Cytokine Signatures of Tertian Malaria Infection Profiled During Pregnancy
By LabMedica International staff writers Posted on 27 May 2020 |
Image: The Cytokine Magnetic 30-Plex Panel is specifically designed for quantifying human cytokines, chemokines and growth factors in serum, plasma, and tissue culture supernatant (Photo courtesy of Invitrogen).
Malaria caused by Plasmodium vivax is a neglected tropical disease, especially during pregnancy, of worldwide distribution. P. vivax is a protozoal parasite and a human pathogen. This parasite is the most frequent and widely distributed cause of recurring malaria.
Severe vivax malaria or tertian malaria is associated with inflammatory responses but in pregnancy immune alterations make it uncertain as to what cytokine signatures predominate, and how the type and quantity of blood immune mediators influence delivery outcomes.
Medical scientists at the Hospital Clínic de Barcelona (Barcelona, Spain) and their international colleagues measured the plasma concentrations of a set of thirty-one biomarkers, comprising cytokines, chemokines and growth factors, in 987 plasma samples from a cohort of 572 pregnant women from five malaria-endemic tropical countries and related these concentrations to delivery outcomes (birth weight and hemoglobin levels) and malaria infection.
The biomarkers were analyzed in thawed plasmas with a multiplex suspension detection system Cytokine Magnetic 30-Plex Panel (Invitrogen, Madrid, Spain) which allows the detection of different biomarker. In addition, the cytokine TGF-β1 was analyzed in all plasmas except those from India, with a DuoSet ELISA kit (R&D Systems, Minneapolis, MN, USA). P. vivax and P. falciparum (studied as a possible confounder in co-infected women) parasitaemia were assessed at every visit in Giemsa-stained blood slides that were read onsite. Submicroscopic malaria infections were also determined at enrolment and delivery by real time-PCR in a group of participants, which included the immunological subcohort. Malaria symptoms and hemoglobin (Hb, g/dL) levels were also recorded at enrolment and delivery, as well as neonatal birth weight (g).
The team reported that at recruitment, they found that P. vivax–infected pregnant women had higher plasma concentrations of proinflammatory (IL-6, IL-1β, CCL4, CCL2, CXCL10) and TH1-related cytokines (mainly IL-12) than uninfected women. This biomarker signature was essentially lost at delivery and was not associated with birth weight or hemoglobin levels. Anti-inflammatory cytokines (IL-10) were positively associated with infection and poor delivery outcomes. CCL11 was the only biomarker to show a negative association with P. vivax infection and its concentration at recruitment was positively associated with hemoglobin levels at delivery. Birth weight was negatively associated with peripheral IL-4 levels at delivery.
The authors concluded that their data showed that while TH1 and pro-inflammatory responses are dominant during P. vivax infection in pregnancy, anti-inflammatory cytokines may compensate excessive inflammation avoiding poor delivery outcomes, and skewness toward a TH2 response that may trigger worse delivery outcomes. CCL11, a chemokine largely neglected in the field of malaria, emerges as an important marker of exposure or mediator in this condition. The study was published on May 4, 2020 in the journal PLOS Neglected Tropical Diseases.
Related Links:
Hospital Clínic de Barcelona
Invitrogen
R&D Systems
Severe vivax malaria or tertian malaria is associated with inflammatory responses but in pregnancy immune alterations make it uncertain as to what cytokine signatures predominate, and how the type and quantity of blood immune mediators influence delivery outcomes.
Medical scientists at the Hospital Clínic de Barcelona (Barcelona, Spain) and their international colleagues measured the plasma concentrations of a set of thirty-one biomarkers, comprising cytokines, chemokines and growth factors, in 987 plasma samples from a cohort of 572 pregnant women from five malaria-endemic tropical countries and related these concentrations to delivery outcomes (birth weight and hemoglobin levels) and malaria infection.
The biomarkers were analyzed in thawed plasmas with a multiplex suspension detection system Cytokine Magnetic 30-Plex Panel (Invitrogen, Madrid, Spain) which allows the detection of different biomarker. In addition, the cytokine TGF-β1 was analyzed in all plasmas except those from India, with a DuoSet ELISA kit (R&D Systems, Minneapolis, MN, USA). P. vivax and P. falciparum (studied as a possible confounder in co-infected women) parasitaemia were assessed at every visit in Giemsa-stained blood slides that were read onsite. Submicroscopic malaria infections were also determined at enrolment and delivery by real time-PCR in a group of participants, which included the immunological subcohort. Malaria symptoms and hemoglobin (Hb, g/dL) levels were also recorded at enrolment and delivery, as well as neonatal birth weight (g).
The team reported that at recruitment, they found that P. vivax–infected pregnant women had higher plasma concentrations of proinflammatory (IL-6, IL-1β, CCL4, CCL2, CXCL10) and TH1-related cytokines (mainly IL-12) than uninfected women. This biomarker signature was essentially lost at delivery and was not associated with birth weight or hemoglobin levels. Anti-inflammatory cytokines (IL-10) were positively associated with infection and poor delivery outcomes. CCL11 was the only biomarker to show a negative association with P. vivax infection and its concentration at recruitment was positively associated with hemoglobin levels at delivery. Birth weight was negatively associated with peripheral IL-4 levels at delivery.
The authors concluded that their data showed that while TH1 and pro-inflammatory responses are dominant during P. vivax infection in pregnancy, anti-inflammatory cytokines may compensate excessive inflammation avoiding poor delivery outcomes, and skewness toward a TH2 response that may trigger worse delivery outcomes. CCL11, a chemokine largely neglected in the field of malaria, emerges as an important marker of exposure or mediator in this condition. The study was published on May 4, 2020 in the journal PLOS Neglected Tropical Diseases.
Related Links:
Hospital Clínic de Barcelona
Invitrogen
R&D Systems
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms